Apoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2

Journal of Carcinogenesis

Volumn 4, Issue , 2005, Pages

  Jenny, Marcel ^a   Schwaiger, Wolfgang ^a   Bernhard, David ^a   Wrulich, Oliver A ^a   Cosaceanu, Daria ^b   Fuchs, Dietmar ^a   Ueberall, Florian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Bcl 2; Multicomponent therapeutics; PADMA 28; T cell derived lymphocytic leukaemia cells; Tibetan medicine

Indexed keywords

ACONITUM EXTRACT; ACONITUM NAPELLUS EXTRACT; AEGLE MARMELOS EXTRACT; ANTINEOPLASTIC AGENT; AQUILEGIA VULGARIS EXTRACT; AZADIRACHTA INDICA EXTRACT; CALENDULA EXTRACT; CAMPHOR; CARDAMOM EXTRACT; CETRARIA ISLANDICA EXTRACT; CLOVE EXTRACT; GLYCYRRHIZA GLABRA EXTRACT; HEDYCHIUM SPICATUM EXTRACT; HERBACEOUS AGENT; LETTUCE EXTRACT; MARIGOLD EXTRACT; PADMA 28; PADMA BASIC; PIMENTA DIOICA EXTRACT; PLANT EXTRACT; PLANTAGO LANCEOLATA EXTRACT; POLY(ADENOSINE DIPHOSPHATE RIBOSE); POLYGONUM AVICULARE EXTRACT; POTENTILLA AUREA EXTRACT; PROTEIN BCL 2; PTEROCARPUS SANTALINUS EXTRACT; SAUSSUREA LAPPA EXTRACT; SIDA CORDIFOLIA EXTRACT; TERMINALIA CHEBULA EXTRACT; THALLUS EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN;

ACONITUM; AEGLE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AQUILEGIA; ARTICLE; ATHEROSCLEROSIS; AZADIRACHTA INDICA; CARDAMOM; CELL CYCLE G1 PHASE; CELL NUCLEUS INCLUSION BODY; CELL SURVIVAL; CETRARIA; CHINA; CHRONIC HEPATITIS; CLOVE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GENE OVEREXPRESSION; GLYCYRRHIZA GLABRA; HEDYCHIUM; HERBAL MEDICINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMITTENT CLAUDICATION; LETTUCE; LYMPHATIC LEUKEMIA; MARIGOLD; MEDICINAL PLANT; MITOSIS INHIBITION; OXIDATIVE STRESS; PIMENTA; PLANTAGO; POLYGONUM; POTENTILLA; PTEROCARPUS; RESPIRATORY TRACT INFECTION; SAUSSUREA; SIDA; T CELL LEUKEMIA; TERMINALIA CHEBULA; THALLUS; VALERIANA OFFICINALIS;

EID: 26844548726     PISSN: 14773163     EISSN: 14773163     Source Type: Journal    
DOI: 10.1186/1477-3163-4-15     Document Type: Article

References (20)

1. Drabaek H. Mehlsen J. Himmelstrup H, Winther K: A botanical compound, PADMA-28 increases walking distance in stable intermittent claudication. Angiology 1993, 44:863-7.
2. Gieldanowski J, Dutkiewicz T, Samochowiec L, Wojcicki J: PADMA-28 modifies immunological functions in experimental atherosclerosis in rabbits. Arch Immunol Ther Exp 1992, 40:291-295.
3. Gladysz A, Juszczyk J, Brzosko WJ: Influence of PADMA 28 on Patients with Chronic Active Hepatitis B. Phytotherapy Research 1993, 7:44-47.
4. Suter M, Richter C: Anti- and pro-oxidative properties of PADMA 28, a Tibetan herbal formulation. Redox Rep 2000, 5:17-22.
5. Moeslinger T, Friedl R, Volf I, Brunner M, Koller E, Spieckermann PG: Inhibition of inducible nitric oxide synthesis by the herbal preparation PADMA 28 in macrophage cell line. Can J Physiol Pharmacol 2000, 78:861-866.
6. Neurauter G, Wirleitner B, Schennach KH, Ueberall F, Fuchs D: PADMA 28 modulates interferon-γ-induced tryptophan degradation and neopterin production in human PBMC in vitro. International Immunopharmacology 2004, 4:833-839.
7. Ginsburg I, Sadovnik M, Sallon S, Milo-Goldzweig I, Mechoulam R, Breuer A, Gibbs D, Varani J, Roberts S, Cleator E, Singh N: PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammapharmacology 1999, 7:47-62.
8. Costantini P, Jacotot E, Decaudin D, Kroemer G: Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000, 92:1042-1053.
9. Green DR, Evan GI: A matter of life and death. Cancer Cell 2002, 1:19-30.
10. Makin G, Dive C: Apoptosis and cancer chemotherapy. Trends in Cell Biol 2001, 11:22-27.
11. Cory S, Huang DCS, Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogenes 2003, 22:8590-8607.
12. Geley S, Hartmann BL, Kofler R: Ceramides induce a form of apoptosis in human acute lymphoblastic leukaemia cells that is inhibited by Bcl-1, but not by CrmA. FEBS Lett 1997, 400:15-18.
13. Strasser-Wozak EMC, Hattmannstorfer R, Hala M, Hartmann BL, Fiegl M, Geley S, Kofler R: Splice site mutation in the glucocorticoid receptor gene causes resistance to glucocorticoid-induced apoptosis in human acute leukaemia cell line. Cancer Res 1995, 55:348-353.
14. Sgonc R, Wick G: Methods for detection of apoptosis. Int Arch Allergy Immunol 1994, 105:327-332.
15. Decker P, Muller S: Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 2002, 3:275-283.
16. Molostvov G, Morris A, Rose P, Basu S: Modulation of Bcl-2 family proteins in primary endothelial cells during apoptosis. Pathophysiol Haemost Thromb 2002, 32:85-91.
17. Kamei T, Inui M, Nakamura S, Okumura K, Goto A, Tagawa T: Interferon-γ and anti-Fas antibody-induced apoptosis in human melanoma cell lines and its relationship to Bcl-2 cleavage and Bak expression. Melanoma Res 2003, 13:153-159.
18. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P: T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002, 9:1069-77.
19. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine 2003, 9:1269-1274.
20. Keith CT, Borisy AA, Stockwell BR: Multicomponent therapeutics for networked systems. Nature Reviews Drug Discovery 2005, 4:1-8.